Stereotaxis

STXS

Market cap $197M

Stereotaxis expands in robotic surgery with Robocath acquisition, aiming to build a comprehensive endovascular platform and unlock growth opportunities.

Stereotaxis, Inc. (STXS) M&A Call Transcript

ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions.

STXS jumps on FDA clearance of Synchrony system, a 4K platform integrating cath lab tech with cloud connectivity to boost workflow, precision and digital surgery.

ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration 510(k) clearance for the Synchrony™ system.

Stereotaxis targets early-stage endovascular robotics with differentiated magnetic navigation for electrophysiology and other minimally invasive procedures. Their MAGiC catheter recently received FDA approval, which I think strengthens STXS's razor-and-blade model by adding recurring disposable revenues. At this point, the bull case rests on STXS growing its early adoption into durable revenues across electrophysiology, endovascular, and connectivity applications.

Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.09 per share a year ago.

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025.

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m.